Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) without an identifiable cause. If not treated after diagnosis, the average life expectancy is 3–5 years. Currently approved drugs for the treatment of IPF are Pirfenidone and Nintedanib, as antifibrotic dru...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1111393/full |
| _version_ | 1811164299556552704 |
|---|---|
| author | Xudan Yang Zhihao Xu Songhua Hu Juan Shen |
| author_facet | Xudan Yang Zhihao Xu Songhua Hu Juan Shen |
| author_sort | Xudan Yang |
| collection | DOAJ |
| description | Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) without an identifiable cause. If not treated after diagnosis, the average life expectancy is 3–5 years. Currently approved drugs for the treatment of IPF are Pirfenidone and Nintedanib, as antifibrotic drugs, which can reduce the decline rate of forced vital capacity (FVC) and reduce the risk of acute exacerbation of IPF. However these drugs can not relieve the symptoms associated with IPF, nor improve the overall survival rate of IPF patients. We need to develop new, safe and effective drugs to treat pulmonary fibrosis. Previous studies have shown that cyclic nucleotides participate in the pathway and play an essential role in the process of pulmonary fibrosis. Phosphodiesterase (PDEs) is involved in cyclic nucleotide metabolism, so PDE inhibitors are candidates for pulmonary fibrosis. This paper reviews the research progress of PDE inhibitors related to pulmonary fibrosis, so as to provide ideas for the development of anti-pulmonary fibrosis drugs. |
| first_indexed | 2024-04-10T15:19:23Z |
| format | Article |
| id | doaj.art-6121352515c143939522be04961a5004 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-10T15:19:23Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-6121352515c143939522be04961a50042023-02-14T16:25:48ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-02-011410.3389/fphar.2023.11113931111393Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosisXudan YangZhihao XuSonghua HuJuan ShenIdiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) without an identifiable cause. If not treated after diagnosis, the average life expectancy is 3–5 years. Currently approved drugs for the treatment of IPF are Pirfenidone and Nintedanib, as antifibrotic drugs, which can reduce the decline rate of forced vital capacity (FVC) and reduce the risk of acute exacerbation of IPF. However these drugs can not relieve the symptoms associated with IPF, nor improve the overall survival rate of IPF patients. We need to develop new, safe and effective drugs to treat pulmonary fibrosis. Previous studies have shown that cyclic nucleotides participate in the pathway and play an essential role in the process of pulmonary fibrosis. Phosphodiesterase (PDEs) is involved in cyclic nucleotide metabolism, so PDE inhibitors are candidates for pulmonary fibrosis. This paper reviews the research progress of PDE inhibitors related to pulmonary fibrosis, so as to provide ideas for the development of anti-pulmonary fibrosis drugs.https://www.frontiersin.org/articles/10.3389/fphar.2023.1111393/fullpulmonary fibrosiscAMPcGMPPDE inhibitoranti-fibrosissenescence |
| spellingShingle | Xudan Yang Zhihao Xu Songhua Hu Juan Shen Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis Frontiers in Pharmacology pulmonary fibrosis cAMP cGMP PDE inhibitor anti-fibrosis senescence |
| title | Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis |
| title_full | Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis |
| title_fullStr | Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis |
| title_full_unstemmed | Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis |
| title_short | Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis |
| title_sort | perspectives of pde inhibitor on treating idiopathic pulmonary fibrosis |
| topic | pulmonary fibrosis cAMP cGMP PDE inhibitor anti-fibrosis senescence |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1111393/full |
| work_keys_str_mv | AT xudanyang perspectivesofpdeinhibitorontreatingidiopathicpulmonaryfibrosis AT zhihaoxu perspectivesofpdeinhibitorontreatingidiopathicpulmonaryfibrosis AT songhuahu perspectivesofpdeinhibitorontreatingidiopathicpulmonaryfibrosis AT juanshen perspectivesofpdeinhibitorontreatingidiopathicpulmonaryfibrosis |